跳至主要内容
临床试验/JPRN-UMIN000012153
JPRN-UMIN000012153已完成未知

Study to confirm the clinical benefit rate(CBR) in the use of Fulvestrant for estrogen receptor positive, HER2 negative Japanese postmenopausal advanced and recurrence breast cancer - Study to confirm the clinical benefit rate(CBR) in the use of Fulvestrant for estrogen receptor positive, HER2 negative Japanese postmenopausal advanced and recurrence breast cancer

Sapporo-Kotoni Breast Clinic0 个研究点目标入组 55 人开始时间: 2013年11月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
55

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1)Taking hormone replacement therapy or selective estrogen receptor 2)History or complications of uncontrolled hypertension, severe heart disease (heart failure, ischemic heart disease, endocarditis, valvular heart disease, pericarditis, and congenital heart disease) 3)Active double cancer 4)Inflammatory breast cancer 5)Bilateral breast cancer 6)History of allergic reactions for drugs and contract medium to be used in this study 7)Medication of investigational new drug for diseases other than breast cancer 8)Patients who are impossible to be enrolled due to psychological diseases or disorder 9)The case judged inappropriate by physicians

研究者

发起方
Sapporo-Kotoni Breast Clinic

相似试验